THC
VENTE TOTALE: 119 311 titres (~32 503 785,18 $ US)
- Insiders
- West Nadja, HANEY CECIL D, Sutaria Saumya, Romo Tammy, Blunt Roy, Lynch Christopher S., BIERMAN JAMES L
- Total bought
- —
- Total sold
- $32,503,785
- Last activity
- 2026-09-02
- Last synced
-
2026-09-08 09:54:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-08
THC shows decent financial health with solid liquidity and improved cash flow efficiency (scores 75/65), but the near-absence of any meaningful event catalyst (score 15, type NONE) severely limits the event-driven…
The first sentence of the analysis written for THC on 2026-09-08 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 82.3% | 39.7% | 38.0% | 36.8% | 37.3% | |
| Ebit Margin | 17.0% | 29.4% | 12.3% | 11.7% | 14.4% | |
| Ebitda Margin | 21.0% | 33.4% | 16.5% | 16.0% | 18.8% | |
| Operating Profit Margin | 16.1% | 28.8% | 12.2% | 12.2% | 14.7% | |
| Pretax Profit Margin | 13.1% | 25.4% | 7.9% | 7.0% | 9.7% | |
| Continuous Operations Profit Margin | 11.1% | 19.7% | 6.4% | 5.2% | 7.6% | |
| Net Profit Margin | 6.6% | 15.5% | 3.0% | 2.1% | 4.7% | |
| Bottom Line Profit Margin | 6.6% | 15.5% | 2.9% | 2.2% | 4.7% | |
| Current Ratio | 1.759 | 1.782 | 1.506 | 1.336 | 1.385 | |
| Quick Ratio | 1.681 | 1.702 | 1.419 | 1.246 | 1.310 | |
| Solvency Ratio | 0.110 | 0.197 | 0.065 | 0.056 | 0.076 | |
| Cash Ratio | 0.646 | 0.700 | 0.258 | 0.192 | 0.463 | |
| Price To Earnings Ratio | 12.730 | 3.823 | 12.574 | 12.706 | 9.554 | |
| Price To Earnings Growth Ratio | -0.241 | 0.009 | 0.223 | -0.231 | 0.076 | |
| Forward Price To Earnings Growth Ratio | -0.241 | 0.009 | 0.223 | -0.231 | 0.076 | |
| Price To Earnings Diluted Ratio | 12.829 | 3.860 | 13.235 | 12.873 | 9.702 | |
| Price To Earnings Diluted Growth Ratio | -0.244 | 0.008 | 0.261 | -0.234 | 0.078 | |
| Price To Book Ratio | 4.245 | 2.933 | 4.777 | 4.568 | 8.489 | |
| Price To Sales Ratio | 0.841 | 0.592 | 0.374 | 0.272 | 0.448 | |
| Price To Free Cash Flow Ratio | 7.081 | 10.961 | 4.733 | 16.253 | 9.590 | |
| Price To Operating Cash Flow Ratio | 5.061 | 5.976 | 3.235 | 4.817 | 5.566 | |
| Debt To Assets Ratio | 0.444 | 0.495 | 0.530 | 0.555 | 0.567 | |
| Debt To Equity Ratio | 3.121 | 3.435 | 9.330 | 13.204 | 15.220 | |
| Debt To Capital Ratio | 0.757 | 0.775 | 0.903 | 0.930 | 0.938 | |
| Long Term Debt To Capital Ratio | 0.756 | 0.753 | 0.902 | 0.929 | 0.938 | |
| Financial Leverage Ratio | 7.032 | 6.937 | 17.607 | 23.779 | 26.828 | |
| Working Capital Turnover Ratio | 6.307 | 7.152 | 10.505 | 11.048 | 9.135 | |
| Operating Cash Flow Ratio | 0.793 | 0.475 | 0.499 | 0.242 | 0.307 | |
| Operating Cash Flow Sales Ratio | 0.166 | 0.099 | 0.116 | 0.056 | 0.080 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.715 | 0.545 | 0.684 | 0.296 | 0.580 | |
| Debt Service Coverage Ratio | 4.501 | 5.087 | 3.019 | 2.640 | 3.077 | |
| Interest Coverage Ratio | 4.189 | 7.211 | 2.786 | 2.621 | 3.111 | |
| Short Term Operating Cash Flow Coverage Ratio | 44.810 | 6.916 | 19.783 | 7.469 | 11.615 | |
| Operating Cash Flow Coverage Ratio | 0.269 | 0.143 | 0.158 | 0.072 | 0.100 | |
| Capital Expenditure Coverage Ratio | 3.505 | 2.199 | 3.161 | 1.421 | 2.383 | |
| Dividend Paid And Capex Coverage Ratio | 3.505 | 2.199 | 3.161 | 1.421 | 2.383 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 6.290 | 3.416 | 6.333 | 6.319 | 6.004 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 82.3% | ▲42.5% | ▲35.5% |
| Ebit Margin | 17.0% | ▼-12.4% | ▲0.1% |
| Ebitda Margin | 21.0% | ▼-12.3% | ▼-0.1% |
| Operating Profit Margin | 16.1% | ▼-12.7% | ▼-0.7% |
| Pretax Profit Margin | 13.1% | ▼-12.3% | ▲0.5% |
| Continuous Operations Profit Margin | 11.1% | ▼-8.6% | ▲1.1% |
| Net Profit Margin | 6.6% | ▼-8.9% | ▲0.2% |
| Bottom Line Profit Margin | 6.6% | ▼-8.9% | ▲0.2% |
| Current Ratio | 1.759 | ▼-0.024 | ▲0.205 |
| Quick Ratio | 1.681 | ▼-0.021 | ▲0.209 |
| Solvency Ratio | 0.110 | ▼-0.087 | ▲0.009 |
| Cash Ratio | 0.646 | ▼-0.054 | ▲0.194 |
| Price To Earnings Ratio | 12.730 | ▲8.908 | ▲2.453 |
| Price To Earnings Growth Ratio | -0.241 | ▼-0.250 | ▼-0.208 |
| Forward Price To Earnings Growth Ratio | -0.241 | ▼-0.250 | ▼-0.208 |
| Price To Earnings Diluted Ratio | 12.829 | ▲8.969 | ▲2.329 |
| Price To Earnings Diluted Growth Ratio | -0.244 | ▼-0.252 | ▼-0.218 |
| Price To Book Ratio | 4.245 | ▲1.312 | ▼-0.757 |
| Price To Sales Ratio | 0.841 | ▲0.249 | ▲0.335 |
| Price To Free Cash Flow Ratio | 7.081 | ▼-3.880 | ▼-2.643 |
| Price To Operating Cash Flow Ratio | 5.061 | ▼-0.915 | ▲0.130 |
| Debt To Assets Ratio | 0.444 | ▼-0.051 | ▼-0.074 |
| Debt To Equity Ratio | 3.121 | ▼-0.314 | ▼-5.741 |
| Debt To Capital Ratio | 0.757 | ▼-0.017 | ▼-0.103 |
| Long Term Debt To Capital Ratio | 0.756 | ▲0.004 | ▼-0.099 |
| Financial Leverage Ratio | 7.032 | ▲0.095 | ▼-9.404 |
| Working Capital Turnover Ratio | 6.307 | ▼-0.845 | ▼-2.523 |
| Operating Cash Flow Ratio | 0.793 | ▲0.318 | ▲0.330 |
| Operating Cash Flow Sales Ratio | 0.166 | ▲0.067 | ▲0.063 |
| Free Cash Flow Operating Cash Flow Ratio | 0.715 | ▲0.170 | ▲0.151 |
| Debt Service Coverage Ratio | 4.501 | ▼-0.586 | ▲0.837 |
| Interest Coverage Ratio | 4.189 | ▼-3.022 | ▲0.205 |
| Short Term Operating Cash Flow Coverage Ratio | 44.810 | ▲37.895 | ▲26.692 |
| Operating Cash Flow Coverage Ratio | 0.269 | ▲0.126 | ▲0.120 |
| Capital Expenditure Coverage Ratio | 3.505 | ▲1.306 | ▲0.971 |
| Dividend Paid And Capex Coverage Ratio | 3.505 | ▲1.306 | ▲0.971 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 6.290 | ▲2.874 | ▲0.618 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $17.91B | $12.23B | $7.68B | $5.22B | $8.73B | |
| Enterprise value | $28.20B | $23.54B | $21.45B | $19.44B | $22.01B | |
| EV / Sales | 1.32x | 1.14x | 1.04x | 1.01x | 1.13x | |
| EV / Op. cash flow | 7.97x | 11.50x | 9.04x | 17.95x | 14.04x | |
| EV / Free cash flow | 11.15x | 21.09x | 13.22x | 60.55x | 24.19x | |
| EV / EBITDA | 6.29x | 3.42x | 6.33x | 6.32x | 6.00x | |
| Net debt / EBITDA | 2.29x | 1.64x | 4.07x | 4.62x | 3.62x | |
| Current ratio | 1.76x | 1.78x | 1.51x | 1.34x | 1.39x | |
| Income quality | 2.52x | 0.50x | 1.81x | 1.08x | 1.06x | |
| Graham number | $128 | $179 | $46 | $30 | $43 | |
| Graham net-net | -$174 | -$154 | -$185 | -$177 | -$171 | |
| Tax burden | 50.2% | 61.0% | 37.8% | 30.6% | 48.4% | |
| Interest burden | 77.3% | 86.4% | 64.2% | 60.2% | 67.2% | |
| Working capital | $3.39B | $3.37B | $2.41B | $1.50B | $1.97B | |
| Invested capital | $23.38B | $22.55B | $21.40B | $20.64B | $20.15B | |
| Return on assets | 4.7% | 11.1% | 2.2% | 1.5% | 3.3% | |
| Operating ROA | 11.7% | 20.8% | 9.1% | 8.5% | 10.5% | |
| Return on tangible assets | 8.2% | 19.0% | 3.7% | 2.6% | 5.4% | |
| Return on equity | 33.3% | 76.7% | 38.0% | 36.0% | 88.9% | |
| Return on invested capital | 11.5% | 18.5% | 8.6% | 7.6% | 9.9% | |
| Return on capital employed | 13.6% | 24.2% | 10.7% | 10.3% | 12.8% | |
| Earnings yield | 7.9% | 26.2% | 8.0% | 7.9% | 10.5% | |
| Free cash flow yield | 14.1% | 9.1% | 21.1% | 6.2% | 10.4% | |
| Capex / Op. cash flow | 28.5% | 45.5% | 31.6% | 70.4% | 42.0% | |
| Capex / Depreciation | 114.0% | 113.8% | 86.3% | 90.6% | 77.0% | |
| Capex / Sales | 4.7% | 4.5% | 3.7% | 4.0% | 3.4% | |
| SG&A / Sales | 40.8% | 42.6% | 2.0% | 2.1% | 2.1% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.5% | 0.3% | 0.3% | 0.3% | 0.3% | |
| Intangibles / Total assets | 42.3% | 41.8% | 41.2% | 42.5% | 39.0% | |
| Days sales outstanding | 44d | 54d | 60d | 66d | 62d | |
| Days payables outstanding | 131d | 38d | 40d | 45d | 39d | |
| Operating cycle | 78d | 64d | 72d | 78d | 73d | |
| Cash conversion cycle | -54d | 26d | 32d | 33d | 35d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+46.5%EV / Sales ▲+16.2%EV / EBITDA ▲+84.1%EV / Op. cash flow ▼-3.533Earnings yield ▼-0.183Graham number ▼-50.620
Profitability
Return on equity ▼-0.434Return on assets ▼-0.063Return on invested capital ▼-0.070Return on capital employed ▼-0.105Operating ROA ▼-0.091Income quality ▲+2.012Tax burden ▼-0.107
Efficiency
Days sales outstanding ▼-10.008Days payables outstanding ▲+93.404Operating cycle ▲+13.456Cash conversion cycle ▼-79.949Capex / Sales ▲+0.002R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.024Net debt / EBITDA ▲+0.654Working capital ▲+14000000.000Invested capital ▲+835000000.000Intangibles / Total assets ▲+0.005
Change over 5 years
Valuation
Market cap ▲+105.3%EV / Sales ▲+17.2%EV / EBITDA ▲+4.8%EV / Op. cash flow ▼-6.070Earnings yield ▼-0.026Graham number ▲+85.174
Profitability
Return on equity ▼-0.556Return on assets ▲+0.014Return on invested capital ▲+0.016Return on capital employed ▲+0.009Operating ROA ▲+0.012Income quality ▲+1.454Tax burden ▲+0.018
Efficiency
Days sales outstanding ▼-17.996Days payables outstanding ▲+92.483Operating cycle ▲+4.135Cash conversion cycle ▼-88.348Capex / Sales ▲+0.014R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.374Net debt / EBITDA ▼-1.329Working capital ▲+1420000000.000Invested capital ▲+3228000000.000Intangibles / Total assets ▲+0.033
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-04-20 | Jonathan Jackson | Sale | $15,001 - $50,000 |
| 2026-04-15 | Jonathan Jackson | Sale | $1,001 - $15,000 |
| 2026-02-11 | Jonathan Jackson | Sale | $1,001 - $15,000 |
| 2025-12-10 | Jonathan Jackson | Purchase | $15,001 - $50,000 |
| 2025-09-03 | Jonathan Jackson | Purchase | $1,001 - $15,000 |
| 2025-06-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-07 Why Tenet Healthcare (THC) is a Top Momentum Stock for the Long-Term Whether you''re a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 2026-09-04 Fast-paced Momentum Stock Tenet (THC) Is Still Trading at a Bargain Tenet (THC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our ''Fast-Paced Momentum at a Bargain'' screen.
- 2026-09-04 THC drinks could soon be harder to find as Congress delays hemp ban again THC drinks are booming, but a looming federal crackdown threatens the industry. THC beverages generated $239 million in measured U.S. retail sales in the 52 weeks through April, up 135% from a year earlier, according to NielsenIQ.
- 2026-09-02 Tenet to Participate in the Wells Fargo Healthcare Conference DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, beginning at 12:45 p.m. Eastern Time. A live webcast and audio archive of the event may be accessed through the investor relations section of Tenet''s website at www.tenethealth.com/investors. The replay will be available for 30 days. About Tenet Healthcare Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services.
- 2026-09-01 New Strong Buy Stocks for September 1st TXO, GS, SNDK, TLS and THC have been added to the Zacks Rank #1 (Strong Buy) List on September 1, 2026.
- 2026-08-31 Should Value Investors Buy Tenet Healthcare (THC) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 2026-08-31 Here''s Why Tenet Healthcare (THC) is a Strong Value Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 2026-08-25 Best Value Stocks to Buy for August 25th SLDE, LEG and THC made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 25th, 2026.
- 2026-08-24 Tenet (THC) is an Incredible Growth Stock: 3 Reasons Why Tenet (THC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 2026-08-20 Tenet (THC) Is Considered a Good Investment by Brokers: Is That True? The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock''s price.